A medical nutriment has supportive value in the treatment of colorectal cancer

F. Jakab, Y. Shoenfeld, Á Balogh, M. Nichelatti, A. Hoffmann, Z. Kahán, K. Lapis, Á Mayer, P. Sápy, F. Szentpétery, A. Telekes, L. Thurzó, A. Vágvölgyi, M. Hídvégi

Research output: Article

46 Citations (Scopus)

Abstract

MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P <0.01; new metastases: 7.6 vs 23.1%, P <0.01; deaths: 12.1 vs 31.7%, P <0.01 ). Survival analysis showed significant improvements in the MSC group regarding progression-free (P = 0.0184) and overall survivals (P = 0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.

Original languageEnglish
Pages (from-to)465-469
Number of pages5
JournalBritish Journal of Cancer
Volume89
Issue number3
DOIs
Publication statusPublished - aug. 4 2003

Fingerprint

Colorectal Neoplasms
Therapeutics
Survival
Survival Analysis
Disease-Free Survival
Observational Studies
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A medical nutriment has supportive value in the treatment of colorectal cancer. / Jakab, F.; Shoenfeld, Y.; Balogh, Á; Nichelatti, M.; Hoffmann, A.; Kahán, Z.; Lapis, K.; Mayer, Á; Sápy, P.; Szentpétery, F.; Telekes, A.; Thurzó, L.; Vágvölgyi, A.; Hídvégi, M.

In: British Journal of Cancer, Vol. 89, No. 3, 04.08.2003, p. 465-469.

Research output: Article

Jakab, F, Shoenfeld, Y, Balogh, Á, Nichelatti, M, Hoffmann, A, Kahán, Z, Lapis, K, Mayer, Á, Sápy, P, Szentpétery, F, Telekes, A, Thurzó, L, Vágvölgyi, A & Hídvégi, M 2003, 'A medical nutriment has supportive value in the treatment of colorectal cancer', British Journal of Cancer, vol. 89, no. 3, pp. 465-469. https://doi.org/10.1038/sj.bjc.6601153
Jakab, F. ; Shoenfeld, Y. ; Balogh, Á ; Nichelatti, M. ; Hoffmann, A. ; Kahán, Z. ; Lapis, K. ; Mayer, Á ; Sápy, P. ; Szentpétery, F. ; Telekes, A. ; Thurzó, L. ; Vágvölgyi, A. ; Hídvégi, M. / A medical nutriment has supportive value in the treatment of colorectal cancer. In: British Journal of Cancer. 2003 ; Vol. 89, No. 3. pp. 465-469.
@article{a37e20d638424d9abf2670aeeeaa0730,
title = "A medical nutriment has supportive value in the treatment of colorectal cancer",
abstract = "MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3{\%}, P <0.01; new metastases: 7.6 vs 23.1{\%}, P <0.01; deaths: 12.1 vs 31.7{\%}, P <0.01 ). Survival analysis showed significant improvements in the MSC group regarding progression-free (P = 0.0184) and overall survivals (P = 0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.",
keywords = "Cohort study, Colorectal cancer, Fermented wheat germ extract, Progression-free and overall survival",
author = "F. Jakab and Y. Shoenfeld and {\'A} Balogh and M. Nichelatti and A. Hoffmann and Z. Kah{\'a}n and K. Lapis and {\'A} Mayer and P. S{\'a}py and F. Szentp{\'e}tery and A. Telekes and L. Thurz{\'o} and A. V{\'a}gv{\"o}lgyi and M. H{\'i}dv{\'e}gi",
year = "2003",
month = "8",
day = "4",
doi = "10.1038/sj.bjc.6601153",
language = "English",
volume = "89",
pages = "465--469",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - A medical nutriment has supportive value in the treatment of colorectal cancer

AU - Jakab, F.

AU - Shoenfeld, Y.

AU - Balogh, Á

AU - Nichelatti, M.

AU - Hoffmann, A.

AU - Kahán, Z.

AU - Lapis, K.

AU - Mayer, Á

AU - Sápy, P.

AU - Szentpétery, F.

AU - Telekes, A.

AU - Thurzó, L.

AU - Vágvölgyi, A.

AU - Hídvégi, M.

PY - 2003/8/4

Y1 - 2003/8/4

N2 - MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P <0.01; new metastases: 7.6 vs 23.1%, P <0.01; deaths: 12.1 vs 31.7%, P <0.01 ). Survival analysis showed significant improvements in the MSC group regarding progression-free (P = 0.0184) and overall survivals (P = 0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.

AB - MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P <0.01; new metastases: 7.6 vs 23.1%, P <0.01; deaths: 12.1 vs 31.7%, P <0.01 ). Survival analysis showed significant improvements in the MSC group regarding progression-free (P = 0.0184) and overall survivals (P = 0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.

KW - Cohort study

KW - Colorectal cancer

KW - Fermented wheat germ extract

KW - Progression-free and overall survival

UR - http://www.scopus.com/inward/record.url?scp=0041475739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041475739&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601153

DO - 10.1038/sj.bjc.6601153

M3 - Article

C2 - 12888813

AN - SCOPUS:0041475739

VL - 89

SP - 465

EP - 469

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -